Due to the above, the Company, together with CMO Kirsten Harting, who has also been part of Alzinova's management team, has jointly agreed that the employment will be terminated. Recruitment of a replacement has begun.

"We would like to thank Kirsten for the good work she has done and wish her the best of luck in the challenges ahead. Now that the Company is entering the next important and exciting phase, it is extremely important that we have the right resources in place in Gothenburg, which will give us the best possible conditions to drive our projects forward", says Alzinova's CEO Tord Labuda.

For further information, please contact:
Tord Labuda, CEO
E-mail: tord.labuda@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com